We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
β-Adrenergic Receptor Gene Polymorphisms and β-Blocker Treatment Outcomes in Hypertension.
- Authors
Pacanowski, M. A.; Gong, Y.; Cooper-DeHoff, R. M.; Schork, N. J.; Shriver, M. D.; Langaee, T. Y.; Pepine, C. J.; Johnson, J. A.
- Abstract
Numerous studies have demonstrated that β1- and β2-adrenergic receptor gene (ADRB1 and ADRB2) variants influence cardiovascular risk and β-blocker responses in hypertension and heart failure. We evaluated the relationship between ADRB1 and ADRB2 haplotypes, cardiovascular risk (death, nonfatal myocardial infarction (MI), and nonfatal stroke), and atenolol-based vs. verapamil sustained-release (SR)-based antihypertensive therapy in 5,895 coronary artery disease (CAD) patients. After an average of 2.8 years, death rates were higher in patients carrying the ADRB1 Ser49-Arg389 haplotype (hazard ratio (HR) 3.66, 95% confidence interval (95% CI) 1.68–7.99). This mortality risk was significant in patients randomly assigned to verapamil SR (HR 8.58, 95% CI 2.06–35.8) but not atenolol (HR 2.31, 95% CI 0.82–6.55), suggesting a protective role for the β-blocker. ADRB2 haplotype associations were divergent within the treatment groups but did not remain significant after adjustment for multiple comparisons. ADRB1 haplotype variation is associated with mortality risk, and β-blockers may be preferred in subgroups of patients defined by ADRB1 or ADRB2 polymorphisms.Clinical Pharmacology & Therapeutics (2008); 84, 6, 715–721 doi:10.1038/clpt.2008.139
- Publication
Clinical Pharmacology & Therapeutics, 2008, Vol 84, Issue 6, p715
- ISSN
0009-9236
- Publication type
Academic Journal
- DOI
10.1038/clpt.2008.139